David Bakhshinyan
Overview
Explore the profile of David Bakhshinyan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakhshinyan D, Suk Y, Kuhlmann L, Adile A, Ignatchenko V, Custers S, et al.
Acta Neuropathol Commun
. 2023 Oct;
11(1):169.
PMID: 37872586
No abstract available.
2.
Bakhshinyan D, Suk Y, Kuhlmann L, Adile A, Ignatchenko V, Custers S, et al.
Acta Neuropathol Commun
. 2023 Jul;
11(1):111.
PMID: 37430373
Medulloblastoma (MB) is the most common type of malignant pediatric brain cancer. The current standard of care (SOC) involves maximal safe resection and chemoradiotherapy in individuals older than 3 years,...
3.
Adile A, Bakhshinyan D, Suk Y, Uehling D, Saini M, Aman A, et al.
J Neurooncol
. 2023 Jun;
163(3):635-645.
PMID: 37354357
Purpose: Medulloblastomas (MBs) constitute the most common malignant brain tumor in children and adolescents. MYC-amplified Group 3 MBs are characterized by disease recurrence, specifically in the leptomeninges, whereby patients with...
4.
Kameda-Smith M, Zhu H, Luo E, Suk Y, Xella A, Yee B, et al.
Nat Commun
. 2023 Jan;
14(1):136.
PMID: 36627300
No abstract available.
5.
Kameda-Smith M, Zhu H, Luo E, Suk Y, Xella A, Yee B, et al.
Nat Commun
. 2022 Dec;
13(1):7506.
PMID: 36473869
Pediatric medulloblastoma (MB) is the most common solid malignant brain neoplasm, with Group 3 (G3) MB representing the most aggressive subgroup. MYC amplification is an independent poor prognostic factor in...
6.
Gwynne W, Suk Y, Custers S, Mikolajewicz N, Chan J, Zador Z, et al.
Cancer Cell
. 2022 Nov;
40(12):1488-1502.e7.
PMID: 36368321
MYC-driven medulloblastoma (MB) is an aggressive pediatric brain tumor characterized by therapy resistance and disease recurrence. Here, we integrated data from unbiased genetic screening and metabolomic profiling to identify multiple...
7.
Qazi M, Salim S, Brown K, Mikolajewicz N, Savage N, Han H, et al.
Cell Rep
. 2022 Sep;
40(13):111420.
PMID: 36170831
Recurrence of solid tumors renders patients vulnerable to advanced, treatment-refractory disease state with mutational and oncogenic landscape distinctive from initial diagnosis. Improving outcomes for recurrent cancers requires a better understanding...
8.
Seyfrid M, Maich W, Shaikh V, Tatari N, Upreti D, Piyasena D, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35017149
Purpose: Glioblastoma (GBM) patients suffer from a dismal prognosis, with standard of care therapy inevitably leading to therapy-resistant recurrent tumors. The presence of cancer stem cells (CSCs) drives the extensive...
9.
Bakhshinyan D, Adile A, Liu J, Gwynne W, Suk Y, Custers S, et al.
Sci Adv
. 2021 Dec;
7(50):eabi5568.
PMID: 34878832
Medulloblastoma (MB) remains a leading cause of cancer-related mortality among children. The paucity of MB samples collected at relapse has hindered the functional understanding of molecular mechanisms driving therapy failure....
10.
Bakhshinyan D, Savage N, Salim S, Venugopal C, Singh S
Front Oncol
. 2021 Jan;
10:603738.
PMID: 33489908
During embryonic development, radial glial precursor cells give rise to neural lineages, and a small proportion persist in the adult mammalian brain to contribute to long-term neuroplasticity. Neural stem cells...